PD-1 inhibitor-associated myasthenia gravis with acute myocardial injury: a case report

Authors:

Abstract
Background: PD-1 inhibitors can cause serious immune-related adverse events, including myasthenia gravis (MG). The occurrence of myocardial injury during immune checkpoint inhibitor therapy can pose diagnostic challenges. Case presentation: A 65-year-old man with hepatocellular carcinoma developed severe PD-1 inhibitor-associated MG after receiving tislelizumab. During the acute phase, he developed acute myocardial injury, with marked hs-cTnT elevation and new ST-segment depression on electrocardiography, and non-ST-segment elevation myocardial infarction (NSTEMI) was clinically suspected. His myasthenic symptoms gradually improved with immunosuppressive therapy, whereas hs-cTnT remained elevated during follow-up. Seven months after the initial presentation, he developed an ST-segment elevation myocardial infarction due to total occlusion of the proximal left anterior descending artery and underwent percutaneous coronary intervention. Conclusion: This case highlights the need to carefully evaluate the underlying cause of myocardial injury in patients with severe PD-1 inhibitor-associated MG. Persistent hs-cTnT may identify patients at increased cardiovascular risk, although the prognostic significance of this finding requires further investigation.
Funding Information
  • NATCM's Project of High-level Construction of Key TCM Disciplines (zyyzdxk-2023154)
  • Special Project on Chronic Disease Management of Guangdong Provincial Hospital of Traditional Chinese Medicine (YN2024MB009)